Modality
Bispecific Ab
MOA
PD-1i
Target
BCMA
Pathway
Ferroptosis
WilmsMG
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
Mar 2019
→ Jul 2026
Phase 1Current
NCT03345831
1,507 pts·MG
2019-03→2026-07·Active
1,507 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-184mo awayPh2 Data· MG
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1/2
Active
Catalysts
Ph2 Data
2026-07-18 · 4mo away
MG
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03345831 | Phase 1/2 | MG | Active | 1507 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 |